Bit Origin
BTOG
Bakkt Holdings
BKKT
The9 Ltd
NCTY
Abits
ABTS
Intchains Group
ICG
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 49.440
- -1.080-2.14%
Close Feb 18 16:00 ET
- 49.010
- -0.430-0.87%
Post 18:30 ET
3.77BMarket Cap-13.08P/E (TTM)
51.390High49.345Low995.74KVolume51.390Open50.520Pre Close49.72MTurnover1.62%Turnover RatioLossP/E (Static)76.23MShares58.40052wk High5.10P/B3.03BFloat Cap17.86052wk Low--Dividend TTM61.35MShs Float58.400Historical High--Div YieldTTM4.05%Amplitude7.520Historical Low49.931Avg Price1Lot Size
About Akero Therapeutics Company
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488
Websitehttp://www.akerotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Andrew Cheng, M.D.,PhD
- President, Chief Executive Officer and Director
- 8.83M
- Catriona Yale
- Chief Development Officer
- 3.45M
- William R. White, J.D.
- Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
- 4.29M
- Dr. Timothy Rolph, D.Phil.
- Chief Scientific Officer
- 3.49M
- Dr. Jonathan Young, J.D.
- Executive Vice President, Chief Operating Officer and Secretary
- 3.44M
- Patrick Lamy
- Senior Vice President, Commercial Strategy
- --
- Mark T. Iwicki
- Chairman of the Board
- 606.06K
- Dr. Seth L. Harrison, M.D.
- Independent Director
- 568.56K
- Dr. Judy Chou, PhD
- Independent Director
- 571.06K
- Jane Pritchett Henderson
- Independent Director
- 586.06K
- Dr. Yuan Xu, PhD
- Independent Director
- 573.56K
- Tomas J. Heyman
- Independent Director
- 581.06K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 578.56K
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.